South African pharmaceutical firm Aspen Pharmacare has announced a deal with U.S. firm Johnson & Johnson to manufacture its COVID-19 vaccine candidate, if it is approved in South Africa and internationally. In a statement issued on Monday, Aspen said that if ongoing trials bring international health authorities to endorse the J&J vaccine as effective and safe, it would be produced at Aspen's manufacturing facility in Port Elizabeth in South Africa's Eastern Cape province. The company said the facility has a capacity to manufacture more than 300 million doses of the vaccine a year. Johnson & Johnson's test vaccine, Ad26.COV3-S, is one of four different vaccines currently undergoing clinical trials in South Africa. Johnson & Johnson would be responsible for supplying the vaccine in large batches and Aspen would put it into vials and package it for individual doses, pending a final commercial agreement, said the statement issued by Aspen. Aspen chief executive Stephen ...
from Companies https://ift.tt/3ewMKit
via IFTTT
No comments:
Post a Comment